The amount of substandard medicines available on the market has been halved in 2017, while some falsified drugs get into circulation via the Internet, said Mikhail Murashko, the Head of Roszdravnadzor.
STADA Arzneimittel AG was informed by Gedeon Richter Plc. that the European Medicines Agency (EMA) has accepted the regulatory resubmission of its proposed biosimilar to Amgen's Neulasta (pegfilgrastim).
FarmaTrust, a UK blockchain startup, has officially signed a partnership with the Mongolian government to pilot a one-year project aimed at preventing the creation and distribution of counterfeit medications.
Celltrion, Inc., a South Korean biopharmaceutical company, announced that the European Commission approved Herzuma (trastuzumab biosimilar) for the treatment of patients with early breast cancer or metastatic gastric cancer
GW Pharmaceuticals, a biopharma company focused on developing therapeutics from its cannabinoid product platform, announced that the EMA has accepted for review the Marketing Authorization Application for Epidiolex
The Russian Ministry of Health began to prepare a draft law on amendments to the Criminal Code of the Russian Federation in order to fight the circulation of falsified, counterfeit, substandard, and unregistered medicinal products.
European comission published a report on the application of penalties for those involved in the production and circulation of falsified medicines published. The report shows a wide variation in penalties across the EU.